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Objective The aim of the study is to identify an association between inpatient opioid
consumption and prescription at discharge after vaginal delivery (VD) and cesarean
delivery (CD).
Methods This retrospective cohort study included women with an active inpatient
opioid order after VD or CD between July and October of 2018 at a single academic
tertiary hospital. Women with opioid use disorder, 3rd or 4th degree lacerations,
wound complications, and peripartum hysterectomy were excluded. Oxycodone 5-mg
(mg) tablets consumed postpartum and prescribed at discharge and sociodemographics were recorded. Primary outcome was the number of oxycodone 5-mg tablets
prescribed at discharge. Outcomes were analyzed using multivariable logistic regression between quartiles of inpatient opioid consumption.
Results A total of 437 patients were included: 169 patients underwent VD, and 268
underwent CD. For VD and CD, women in the highest quartile of inpatient opioid
consumption were more likely Black compared with the lowest quartile (p ¼ 0.006 and
p ¼ 0.004, respectively). No association existed between inpatient opioid use and
number of tablets prescribed at discharge for VD or CD (odds ratio [OR] 0.22 [95%
conﬁdence interval or CI 0.02–2.17] and OR 1.04 [95% CI 0.85–1.32], respectively).
Conclusion The number of opioid tablets prescribed at discharge had no association
with inpatient postpartum consumption after VD or CD.

Of the 63,000 people who died from drug overdose in 2016,
approximately 66% involved opioids,1 and 40% of opioid
overdoses were from prescription opioids.2 This demonstrates the role of medical providers in the current opioid
epidemic. Each year in the United States, there are over 3
million vaginal deliveries and 1.3 million cesarean sections,
and up to 27and 75.5% of women ﬁlled an opioid prescription
after delivery at discharge for vaginal deliveries and cesarean

sections, respectively.2 As such, opioid prescribing for postdelivery pain management is one of the most common
sources of prescribed opioids nationally.3,4 It is especially
relevant for the practicing obstetrician as 1 in 300 opioid
naïve patients becomes long-term opioid users.5 There are
no national guidelines for outpatient opioid prescribing, with
an optimal amount of post-delivery opioids not yet identiﬁed
for the practicing obstetrician. However, recently published

received
May 21, 2020
accepted after revision
July 20, 2020

Copyright © 2020 by Thieme Medical
Publishers, Inc., 333 Seventh Avenue,
New York, NY 10001, USA.
Tel: +1(212) 760-0888.

DOI https://doi.org/
10.1055/s-0040-1716906.
ISSN 2157-6998.

e275

e276

Inpatient Postpartum Opioid Usage after Delivery

Veade et al.

Committee Opinion from ACOG (American College of Obstetricians and Gynecologists) recommends utilizing a multimodal stepwise approach to limit opioids administered
especially after cesarean delivery (CD).5 In other surgical
specialties, the Centers for Disease Control and Prevention
(CDC) recommends 3 days or less duration of treatment for
acute pain with an opioid, with a maximum duration of
7 days.6 Applying these recommendations to postpartum
patients would suggest that obstetric patients should experience the majority of their opioid consumption setting
inpatient after delivery,7 and that obstetricians overprescribe opioids after cesarean section and vaginal delivery
(VD).3,4,8
One strategy to optimize post-delivery opioids prescription is to tailor the number of opioid tablets prescribed
according to inpatient usage to ensure patient pain is appropriately treated without providing excess opioids. Indeed,
quantifying inpatient opioid consumption after vaginal and
CD could be helpful in guiding the amount of tablets for postdischarge opioid prescribing. However, there is little data
evaluating inpatient opioid usage after VD and cesarean
sections in relation to the amount of opioids prescribed at
discharge. One prospective observational cohort study of 179
women did suggest little association between inpatient
opioid usage and discharge prescribing amount after CD.9
Another retrospective study of 12,326 women highlighted
approximately 45.7% of women after VD who received an
opioid at time of discharge used 0-mg morphine equivalents
(MMEs) on ﬁnal day of discharge.10 Our study adds to the
previous studies and more closely examines total inpatient
postpartum opioid consumption. This study aims to evaluate
whether there is an association between the amount of
tablets consumed during the entire inpatient postpartum
admission and the amount of tablets prescribed at hospital
discharge after both VD and cesarean section.

Materials and Methods
This retrospective cohort study included women who had an
active inpatient opioid order in the electronic medical record
(EMR) after a VD or cesarean section between July, 2018 and
October, 2018 at a single academic tertiary care center. The
dates selected were reﬂective of initiation of a central electronic
medical record at our institution, allowing for identiﬁcation of
eligible patients. Women were excluded if they had a history of
opioid usage prior to delivery, third- or fourth- degree laceration at time of delivery, wound complications, and peripartum
hysterectomy. Opioid usage prior to delivery was deﬁned as a
known diagnosis of opioid use disorder or receipt of more than
one opioid prescription during pregnancy, as identiﬁed per
review of our comprehensive EMR, which integrates inpatient
and outpatient care at our institution. Wound complications
were deﬁned as wound infections, seromas, or hematomas
requiring surgical or medical intervention. The Washington
University in St. Louis Human Research Protection Ofﬁce
approved this study (IRB # 201901055).
The medical records of all women who delivered within
the study period were reviewed to identify eligible women.
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Participant clinical and sociodemographic information was
extracted from qualifying subjects. Sociodemographic data
included age, race, body mass index (BMI), insurance payer,
length of post-delivery stay in days, and the discharge opioid
prescriber (intern, resident, or attending). Race was reported
as “Black” versus “White” as recorded in our EMR; the
minority of women who were neither Black nor White
were excluded given low prevalence at our institution.
The number of opioid tablets consumed post-delivery
while inpatient and prescribed at discharge were recorded.
At our institution, 5-mg oxycodone tablets are the most
prescribed inpatient opioid: 94.6 and 97.0% of prescriptions
are 5-mg oxycodone for VD and cesarean section, respectively. Therefore, other forms of opioids were converted to MME
before being converted to 5-mg oxycodone tablets for ease of
comparison. The primary outcome of this study was the
number of oxycodone 5-mg tablets prescribed at discharge
after delivery, stratiﬁed by mode of delivery.
At our academic institution, our hospital obstetrical practice consists of both private and nonprivate patients. Routine
postpartum care universally involves nurse practitioners and
residents. It is routine to order oxycodone 5-mg tablets for
post-CD as needed for pain in postpartum order sets, while
not ordered for after VD. Inpatient postpartum opioids after
VD are ordered at physician discretion. Additionally, acetaminophen and ibuprofen are routinely ordered as scheduled after CD, and as needed after VD for ﬁrst line pain
control. If any opioid is prescribed at discharge, both acetaminophen and ibuprofen are prescribed as ﬁrst line agents,
and patients counseled on pain management. However,
there are no guidelines or recommendations for the amount
of opioid tablets prescribed at discharge after VD. For CD,
there are no formal guidelines or recommendations either,
but an arbitrary number is selected by the discharging
physician. A “common practice” of discharge is 5-mg oxycodone tablets after CD ranging from 10 to 30 tablets. Ultimately, all discharge opioid prescriptions are at the
discretion of discharging physician. Discharge provider
includes either a resident physician, nurse practitioner, or
attending physician, with most commonly prescribing provider a nurse practitioner or resident physician.
Participants were stratiﬁed by mode of delivery into quartiles by inpatient opioid usage. Demographic and baseline
clinical data were compared between women who had the
highest versus lowest quartile of inpatient opioid usage using a
chi-square test or Fisher’s exact test for categorical variables, as
appropriate, and the Student’s t-test or Mann-Whitney U-test
for continuous variables. Multivariable regression models
stratiﬁed women by inpatient opioid use and mode of delivery
and analyzed primary outcomes, which were the number of
opioid tablets prescribed at discharge. For women who had VD,
though there were differences in age, maternal BMI and race,
obstetric lacerations, and obstetric complications (such as
postpartum operating room procedure, hemorrhage, episiotomy, or cervical laceration) between the study groups, multivariable analyses were not performed due to small numbers in
the study population. Sensitivity analyses were then performed excluding women who underwent bilateral tubal
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ligation (BTL) after VD. For women who had CD, multivariable
logistic regression was adjusted for race and day of postpartum
discharge. Sensitivity analyses were then performed excluding
women who were discharged at or after postoperative day ﬁve
after CD.

Results
In total, 437 patients met inclusion criteria. Of these, 169
patients underwent VD, and 268 underwent CD.

Vaginal Delivery
Among the 169 included patients, the median number of
oxycodone 5-mg tablets consumed as an inpatient was one
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tablet (interquartile range [IQR] 0, 3). However, 30.1%
(51/169) of patients received a prescription for oral opioids
on discharge. The median number of tablets prescribed at
discharge among patients who received a prescription was
15 (IQR 10, 20). Delivery, nearly one-third (n ¼ 16; 32%)
received a postpartum opioid prescription, with a median
of 10 tablets (IQR 5, 16.25).
In ►Table 1, sociodemographic characteristics of the top
quartile of post-VD inpatient opioid users—who consumed
greater than or equal to three tablets (n ¼ 58)—are compared
with the lowest quartile, who consumed 0 tablets (n ¼ 50).
Highest quartile inpatient opioid users were more likely to be
Black (p ¼ 0.006). The number of tablets consumed as an
inpatient were not related to mode of delivery (spontaneous

Table 1 Sociodemographics of patients who underwent vaginal delivery by quartile of inpatient opioid usage
Highest quartile
(three tablets or more)
(n ¼ 58)

Lowest quartile (0 tablets)
(n ¼ 50)

p-Value

29 (25, 32)

32.5 (26, 35)

0.03

White

17 (29.3)

13 (26.0)

0.006

Black

39 (67.2)

25 (50.0)

Other

2 (332.5)

12 (24.0)

Private insurance

15 (25.9)

18 (36.0)

Public insurance

42 (72.4)

29 (58.0)

Other

1 (1.7)

3 (6.0)

31.6 (26.7, 36.2)

29.8 (24.8, 36.6)

0.6

Spontaneous

52 (89.7)

48 (96.0)

0.2

Vacuum assisted

3 (5.2)

2 (4.0)

Forceps assisted

3 (5.2)

0 (0.0)

Maternal age at delivery (median [SD]) years
Race/ethnicity (n [%])

Insurance type (n [%])

Maternal BMI (median [IQR])

0.2

Type of delivery (n [%])

Type of laceration (n [%])

(missing 1 from lowest quartile)

Intact

28 (48.3)

24 (49.0)

1st degree

3 (5.2)

8 (16.3)

2nd degree

12 (20.7)

13 (26.5)

3rd degree

1 (1.7)

1 (2.0)

4th degree

1 (1.7)

0 (0.0)

Other (periurethral, sulcal)

13 (22.4)

3 (6.1)

None

43 (74.1)

40 (80.0)

BTL

14 (24.1)

5 (10.0)

Cervical laceration

0 (0.0)

2 (4.0)

Other (episiotomy, IUFD, DVT, trauma)

1 (1.7)

3 (6.0)

Intern

23 (39.7)

15 (30.0)

Resident

23 (39.7)

28 (56.0)

Attending

12 (20.7)

7 (14.0)

0.1

Complications (n [%])
0.08

Discharge opioid subscribing provider (n [%])
0.2

Abbreviations: BTL, bilateral tubal ligation; DVT, deep venous thrombosis; IQR, interquartile range; IUFD, intrauterine fetal death; SD, standard
deviation.
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Table 2 Multivariate regression of number of tablets prescribed at discharge by quartile of inpatient opioid usage after vaginal
delivery
# Oxycodone 5-mg tablets
prescribed at discharge (n [%])

Highest
quartile (n ¼ 58)

Lowest quartile (0 tablets)
(n ¼ 50)

Unadjusted OR

0

31 (53.5)

34 (68.0)

0.91 (0.56–1.48)

1–9

1 (1.7)

5 (10.0)

0.22 (0.02–1.98)

10–19

16 (27.6)

7 (14.0)

2.51 (0.91–6.90)

20–29

6 (10.3)

4 (8.0)

1.65 (0.42–6.38)

30

4 (6.9)

0 (0.0)

–

# Oxycodone 5-mg tablets prescribed
at discharge (n [%])

Highest quartile (n ¼ 44)

Lowest quartile (0 tablets)
(n ¼ 45)

Unadjusted OR

0

27 (61.4)

33 (73.3)

0.82 (0.49–1.36)

1–9

1 (2.3)

3 (6.7)

0.41 (0.040–4.14)

10–19

9 (20.5)

5 (11.1)

2.20 (0.66–7.35)

Excluding women who underwent BTL

20–29

4 (9.1)

4 (8.9)

1.22 (0.28–5.35)

30

3 (6.8)

0 (0.0)

–

Abbreviations: BTL, bilateral tubal ligation; OR, odds ratio.

or operative VD), degree of perineal laceration, complications such as cervical laceration or BTL, or discharge prescribing physician. As shown in ►Table 2, multivariate
analysis demonstrated no association between inpatient
opioid usage quartile and the number of tablets prescribed
at discharge. In a sensitivity analysis excluding patients who
underwent BTL, these ﬁndings were unchanged.

Cesarean Delivery
Of the 268 patients who had a CD, the median number of
oxycodone 5-mg tablets consumed during the inpatient
postoperative period was seven tablets (IQR 2.5, 12), and
94.7% (254/268) of women received an oral opioid prescription at discharge. The median number of oxycodone 5-mg
tablets prescribed among those receiving a prescription at
discharge was 20 tablets (IQR 20, 21). Of the 14.6% (39/268)
patients who did not consume any opioid tablets in the
hospital after CD, 89.7% (35/39) received a narcotic prescription at discharge, with a median of 20 oxycodone 5-mg
tablets (IQR 20, 20).
In ►Table 3, the sociodemographic characteristics of top
quartile of post-CD inpatient opioid users—who consumed
greater than or equal to 12 tablets (n ¼ 74)—are compared
with the lowest quartile, who consumed less than 2.5 tablets
(n ¼ 67). Highest quartile of inpatient opioid users were
more likely to be Black (p ¼ 0.004). Patients who stayed until
postoperative day 4 were more likely to be in the highest
quartile of inpatient opioid users when compared with
women who were discharged either on or after postoperative
day 5 or on less than postoperative day 3 (p ¼ 0.02). There
was no association between inpatient opioid usage and type
of insurance or BMI. ►Table 4 presents analyses on our
primary outcome. There was no association between inpatient opioid usage after CD and the number of tablets
prescribed at discharge, even after adjusting for race and
American Journal of Perinatology Reports
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day of discharge. In a sensitivity analysis excluding patients
who were discharged after postoperative day 5, the ﬁndings
were unchanged.

Discussion
In this retrospective study, there was no correlation between
inpatient opioid consumption and the amount of opioids
prescribed at time of discharge after vaginal or CD. Furthermore, postpartum patients within our academic institution
received enough oral opioids to last up to 8 days after
delivery, exceeding the recommendation of 4 to 7 days of
acute pain treatment as per the CDC, regardless of inpatient
opioid consumption. Our results also suggest that implementation of standard prescribing after CD is potentially
leading to overprescribing; while subjective provider prescribing after VD also leads to overprescribing lending to a
need for employing more applicable methodology at the
time of discharge.
The median amount of 5-mg oxycodone tablets prescribed was 15 and 20 among those who received a discharge
prescription after VD and CD, respectively. This is despite the
median inpatient opioid usage being 1 tablet (IQR 0–3) and 7
tablets (IQR 2.5–12) for vaginal and cesarean deliveries,
respectively. One potential explanation of such difference
between inpatient usage and opioids prescribed at discharge
is that providers may be accustomed to using a “one size ﬁts
all” prescribing protocol after vaginal and cesarean deliveries, which does not incorporate inpatient opioid use into
discharge prescribing protocols. This is perhaps best demonstrated through those who had a VD and consumed no postdelivery oral opioids receiving a median of 10 (IQR 5–16.25)
tablets at time of discharge. For cesarean sections, nonopioid
users in the postoperative setting had a median of 20 tablets
(IQR 20–21) prescribed at discharge, the same number for
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Table 3 Sociodemographics of patients who underwent cesarean delivery by quartile of inpatient opioid usage

Maternal age at delivery (median [SD]) years

Highest quartile (12 tablets)
(n ¼ 74)

Lowest quartile (<2.5 tablets)
(n ¼ 67)

p-Value

30 (26, 33)

30 (24, 35)

0.9

0.004

Race/Ethnicity (n [%])
White

25 (33.8)

40 (59.7)

Black

40 (54.1)

25 (37.3)

Other

9 (12.2)

2 (3.0)

Private insurance

45 (60.8)

44 (65.7)

Public insurance

27 (36.5)

23 (34.3)

Other

2 (2.7)

0 (0.0)

33.8 (29.2, 39.8)

32.3 (26,6, 39.2)

0.3

PPD 3 or less

25 (33.8)

38 (56.7)

0.02

PPD 4

43 (58.1)

26 (38.8)

PPD 5 or more

6 (8.1)

3 (4.5)

Intern

38 (51.4)

37 (55.2)

Resident

22 (29.7)

19 (28.4)

Attending

14 (18.9)

11 (16.4)

Insurance type (n [%])

Maternal BMI (median [IQR])

0.4

Day of discharge (n [%])

Discharge opioid subscribing provider (n [%])
0.9

Abbreviations: IQR, interquartile range; PPD, PPD, postpartum day; SD, standard deviation.

Table 4 Multivariate regression of number of tablets prescribed at discharge by quartile of inpatient opioid usage after cesarean
delivery
# Oxycodone 5-mg tablets
prescribed at discharge (n [%])

Highest quartile
(12 tablets)
(n ¼ 74)

Lowest quartile
(<2.5 tablets)
(n ¼ 67)

Unadjusted OR

Adjusted ORa

0

0 (0.0)

7 (10.5)

–

–

1–10

0 (0.0)

3 (4.5)

–

–

11–20

46 (62.2)

40 (59.7)

1.11 (0.77–1. 42)

1.04 (0.85–1.32)

21–30

26 (35.1)

16 (23.9)

1.41 (0.67–3.00)

1.68 (0.75–3.74)

31

2 (2.7)

1 (1.5)

1.74 (0.15–19.90)

1.85 (0.14–23.84)

# Oxycodone 5-mg tablets
prescribed at discharge (n [%])

Highest quartile
(12 tablets)
(n ¼ 68)

Other (<12 tablets)
(n ¼ 64)

Unadjusted OR

Adjusted ORb

0

0 (0.0)

7 (10.9)

–

–

1–10

0 (0.0)

3 (4.7)

–

–

11–20

42 (61.8)

38 (59.4)

1.10 (0.72–1.48)

1.05 (0.82–1.34)

21–30

25 (36.8)

15 (23.4)

1.51 (0.69–3.28)

1.64 (0.73–3.69)

31

1 (1.5)

1 (1.6)

0.91 (0.05–14.97)

0.69 (0.38–12.69)

Excluding DC after PPD 5

Abbreviations: DC, discharge; OR, odds ratio; PPD, postpartum day.
a
Adjusted for race and day of discharge.
b
Adjusted for race.

routine postoperative oral opioid users. While the IQR after
CD suggests less of a variation of opioid prescribing, the
median number of tablets consumed as an inpatient is still
substantially less. Given it has been demonstrated that after
delivery approximately 3.86 million women each year are at

risk for continued opioid use, it is imperative to bridge the
gap between inpatient usage and opioid prescription at
discharge.4 One shared decision making study by Prabhu
et al suggested one approach to this dilemma, and implemented shared decision making among 51 women after CD,
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which showed 50% decrease in opioids prescribed postoperatively, but still demonstrated median 20 tablets prescribed
after cesarean section after shared decision making.11 This
suggests that additional implementation of review of inpatient opioid usage at time of discharge could more accurately
depict opioid consumption to guide adequate discharge
opioid prescribing after vaginal and CD.9
Our ﬁnding that the number of tablets prescribed at
discharge was not associated with inpatient opioid usage
supports and adds to the current literature, which remains
limited in quantifying inpatient opioid usage after delivery. For
example, Badreldin et al found there was no association
between amount of tablets prescribed at discharge and median
MME consumed in ﬁnal 24 hours after delivery for both vaginal
and cesarean deliveries.9 Even further, they also identiﬁed that
nonopioid users could beneﬁt most from utilizing inpatient
opioid consumption to direct postpartum discharge prescriptions. This study appreciated 45.7 and 18.5% of nonopioid
using patients in the last 24 hours until discharge received an
opioid prescription after vaginal and CD, respectively.10 Our
retrospective study supported these ﬁndings within a different
patient population: our study population was comprised
predominantly of Black women with a high proportion of
women with public insurance whereas the prior study was
comprised mostly of White women with private insurance.
Both studies suggest evaluating inpatient opioid usage as a tool
to tailor postpartum discharge prescribing after delivery.
This study had many strengths. First, our institution has a
centralized electronic medical record, which allowed us to not
only quantify number of tablets consumed during the entire
inpatient postpartum stay, but also exclude women who had a
prior history of opioid use disorder. Second, all data were
abstracted from the medical record by physicians, increasing
the accuracy of our ﬁndings. Third, we included all eligible
women during a prespeciﬁed time period, which limits the risk
of selection bias. Additionally, despite the period of our included
patients starting in July at the time of matriculation of newer
intern physicians, the discharge prescribing physicians were
evenly distributed between intern, resident physician, and
attending physician. However, the study is not without limitations. First, our study is retrospective in nature and was
conducted at a single institution, which may limit the
generalizability of our ﬁndings. Second, we were unable to
incorporate patient-reported pain scores during inpatient hospitalization. Though these subjective pain measurements may
have differed between lowest and highest inpatient opioid users
—which could affect the amount of tablets prescribed at discharge—they are inconsistently reported in the patient medical
record, particularly on or after postpartum day 2 or postoperative day 3. Lastly, we were not able to perform multivariate
regression analysis for VD due to smaller sample size, which can
limit identifying potential confounders.
In sum, our study demonstrated that the amount of opioids
prescribed at discharge had no association with the amount of
opioids consumed during inpatient postpartum stay despite
cofounders. Based on the CDC’s recommendation of acute pain
treatment, patients are likely to have the majority of the acute
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pain episode while inpatient and therefore tailoring patient’s
discharge prescription based on inpatient usage can help
minimize overprescribing while providing adequate pain control. Additional prospective studies implementing prescribing
practices based on inpatient usage and pain scores along with
quantifying post discharge opioid usage are warranted to help
eliminate overprescribing while maximizing adequate pain
control, and to help establish national standards in postpartum
opioid prescribing.
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